Cargando…
Antibody-Drug Conjugates : Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer.
Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. - Discusses the basics, drug delivery strategies, pharmacology and toxicology,...
| Clasificación: | Libro Electrónico |
|---|---|
| Autor principal: | |
| Otros Autores: | |
| Formato: | Electrónico eBook |
| Idioma: | Inglés |
| Publicado: |
New York :
John Wiley & Sons, Incorporated,
2016.
|
| Temas: | |
| Acceso en línea: | Texto completo |
MARC
| LEADER | 00000cam a2200000Mi 4500 | ||
|---|---|---|---|
| 001 | EBOOKCENTRAL_ocn964410742 | ||
| 003 | OCoLC | ||
| 005 | 20240329122006.0 | ||
| 006 | m o d | ||
| 007 | cr |n|---||||| | ||
| 008 | 161126s2016 nyu o 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d RECBK |d OCLCQ |d MERUC |d CUY |d OCLCF |d ICG |d OCLCO |d ZCU |d OCLCQ |d OCLCO |d TKN |d DKC |d OCLCQ |d SGP |d OCLCO |d OCL |d OCLCQ |d OCLCO |d OCLCL | ||
| 020 | |a 9781119060802 | ||
| 020 | |a 111906080X | ||
| 035 | |a (OCoLC)964410742 | ||
| 050 | 4 | |a RS431.A64 | |
| 060 | 1 | 0 | |a QW 575.5.A6 |
| 082 | 0 | 4 | |a 616.994027 |
| 049 | |a UAMI | ||
| 100 | 1 | |a Olivier, Kenneth J. | |
| 245 | 1 | 0 | |a Antibody-Drug Conjugates : |b Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. |
| 260 | |a New York : |b John Wiley & Sons, Incorporated, |c 2016. | ||
| 300 | |a 1 online resource (566 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | 0 | |a Print version record. | |
| 505 | 0 | |a Cover; Title Page; Copyright; Contents; List of Contributors; Preface; Historical Perspective: What Makes Antibody-Drug Conjugates Revolutionary?; Introduction; Early Work in Monoclonal Antibody Development: Ehrlich's Magic Bullets; Use of Monoclonal Antibodies to Identify and Treat Cancer; Linking Monoclonal Antibodies with Cytotoxic Agents; Antibody-Drug Conjugates in the Clinic; Why ADCs Are Revolutionary?; References; Part I 1 What is an Antibody-Drug Conjugate; Chapter 1 Typical Antibody-Drug Conjugates; 1.1 Introduction; 1.1.1 A Simple Concept. | |
| 505 | 8 | |a 1.1.2 Turning Antibodies into Potent Anticancer Compounds1.1.3 What is a Typical ADC and How Does it Act?; 1.1.4 Simple Concept, but Not So Simple to Execute; 1.2 The Building Blocks of a Typical ADC; 1.2.1 The Antibody; 1.2.1.1 Antibody Isotype in ADCs; 1.2.1.2 Functional Activity of the Antibody Moiety in ADCs; 1.2.2 The Payload; 1.2.2.1 DNA-Targeting Payloads; 1.2.2.2 Payloads Targeting Tubulin; 1.2.3 Linker Chemistries; 1.3 Building an ADC Molecule; 1.3.1 Conjugation of Payloads to Antibodies at Lysine Residues; 1.3.2 Conjugation of Payloads to Antibodies at Cysteine Residues. | |
| 505 | 8 | |a 1.4 Attributes of a Typical ADC1.4.1 Structural Attributes of a Typical ADC; 1.4.2 Functional Characteristics of a Typical ADC; 1.4.2.1 In Vitro Properties; 1.4.2.2 In Vivo Efficacy; 1.4.2.3 Pharmacokinetics of ADCs; 1.5 Summary; Acknowledgment; References; Part II Engineering, Manufacturing, and Optimizing Antibody-Drug Conjugates; Chapter 2 Selecting Optimal Antibody-Drug Conjugate Targets Using Indication-Dependent or Indication-Independent Approaches; 2.1 Characteristics of an Optimal ADC Target; 2.2 Indication-Dependent ADC Target Selection. | |
| 505 | 8 | |a 2.3 Indication-Independent ADC Target Selection2.4 Concluding Remarks and Future Directions; Acknowledgments; References; Chapter 3 Antibody-Drug Conjugates: An Overview of the CMC and Characterization Process; 3.1 Introduction; 3.2 ADC Manufacturing Process; 3.2.1 Conjugation; 3.2.2 Conjugation -- Next-Generation Chemistry; 3.2.2.1 Conjugation -- Novel Payloads; 3.2.2.2 Conjugation -- Linker Design; 3.2.3 mAb Engineering; 3.2.4 Purification; 3.2.5 Formulation; 3.3 Characterization; 3.3.1 Quality and Stability Testing; 3.3.2 Biochemical and Microbiological Testing. | |
| 505 | 8 | |a 3.3.3 Extended Characterization3.4 Comparability; 3.5 Concluding Remarks; References; Chapter 4 Linker and Conjugation Technology; and Improvements; 4.1 Overview; 4.2 Noncleavable; 4.3 Cleavable Linkers and Self-Immolative Groups; 4.4 Differences in Therapeutic Window of Cleavable and Noncleavable Linkers; 4.5 Improving Therapeutic Window with Next-Generation Linker Technologies; 4.6 Site-Specific Conjugation, Homogeneous Drug Species, and Therapeutic Window; 4.7 Influence of Linkers on Pharmacokinetics and ADME; 4.8 PEG Linkers to Optimize Clearance, Solubility, and Potency. | |
| 500 | |a 4.9 Linkers to Optimize for Drug Resistance. | ||
| 520 | |a Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells. - Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies- Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging- Includes case studies of ADCs in oncology drug development- Features contributions from highly-regarded experts on the frontlines of ADC research and development. | ||
| 590 | |a ProQuest Ebook Central |b Ebook Central Academic Complete | ||
| 650 | 0 | |a Antibody-toxin conjugates. | |
| 650 | 0 | |a Monoclonal antibodies. | |
| 650 | 0 | |a Antineoplastic agents. | |
| 650 | 0 | |a Tumors |x Treatment. | |
| 650 | 0 | |a Antimitotic agents. | |
| 650 | 2 | |a Immunoconjugates | |
| 650 | 2 | |a Immunotoxins | |
| 650 | 2 | |a Antibodies, Monoclonal | |
| 650 | 2 | |a Antimitotic Agents | |
| 650 | 2 | |a Antineoplastic Agents | |
| 650 | 6 | |a Conjugués antitoxines. | |
| 650 | 6 | |a Anticorps monoclonaux. | |
| 650 | 6 | |a Anticancéreux. | |
| 650 | 6 | |a Tumeurs |x Traitement. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Antimitotic agents |2 fast | |
| 650 | 7 | |a Antibody-toxin conjugates |2 fast | |
| 650 | 7 | |a Antineoplastic agents |2 fast | |
| 650 | 7 | |a Monoclonal antibodies |2 fast | |
| 650 | 7 | |a Tumors |x Treatment |2 fast | |
| 700 | 1 | |a Hurvitz, Sara A. | |
| 758 | |i has work: |a Antibody-drug conjugates (Text) |1 https://id.oclc.org/worldcat/entity/E39PCGDvk9h3JKDwVpFj7XdDHK |4 https://id.oclc.org/worldcat/ontology/hasWork | ||
| 776 | 0 | 8 | |i Print version: |a Olivier, Kenneth J. |t Antibody-Drug Conjugates : Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer. |d New York : John Wiley & Sons, Incorporated, ©2016 |z 9781119060680 |
| 856 | 4 | 0 | |u https://ebookcentral.uam.elogim.com/lib/uam-ebooks/detail.action?docID=4745624 |z Texto completo |
| 938 | |a EBL - Ebook Library |b EBLB |n EBL4745624 | ||
| 938 | |a Recorded Books, LLC |b RECE |n rbeEB00692299 | ||
| 994 | |a 92 |b IZTAP | ||